We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Biogen MS drug Plegridy OK'd; can it compete?

News

Executive Summary

The wait is over for Biogen Idec on its latest multiple sclerosis drug Plegridy (peginterferon beta-1a), with the Cambridge, Massachusetts company receiving word late on 15 August the FDA approved the medicine as a treatment for relapsing forms of the disease – the first and only pegylated beta interferon OK'd for the condition in the US.